• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Thatcher, Nick
    Mene, A R
    Banerjee, Saumitra S
    Craig, P
    Gleave, N
    Orton, C
    Affiliation
    Cancer Research Campaign, Department of Medical Oncology, Christie Hospital and Holt Radium Institute, Manchester.
    Issue Date
    1986-02
    
    Metadata
    Show full item record
    Abstract
    One hundred and fifteen patients with histologically proven primary cutaneous melanoma were entered into a randomized prospective study following surgical removal of clinically obvious regional metastases. The study started in 1977 and was completed in June 1982. Fifty-eight patients (10 with regional skin metastases and 48 with regional node metastases) were in the control group and 57 (15 regional skin, and 42 regional node metastases) received adjuvant C. parvum. Other clinical features were well balanced for each group. C. parvum, 2 mg/m2 IV was repeated eight times at three weekly intervals. The schedule was based on previous work which indicated significant increase in killer cell activity. There was no serious toxicity and 22 patients exhibited tachyphylaxis. Seventeen patients in the control group (11 tumour free) are alive at 24-80 months, and 20 patients in the C. parvum group (12 tumour free) are alive 24-76 months from randomization. No statistically significant difference (P greater than 0.05) was observed between the two patient groups for overall survival (median 26 months) or relapse free survival (median 8 months) from the date of randomization. Nor was the overall survival from the date of primary surgery (median 52 months, range 4-237) or the relapse free survival, median 28 months, range 2-225, significantly different between the two groups of patients. The relapse pattern in the two groups, and survival after relapse were no different though the response rate to actinomycin D and DTIC chemotherapy was significantly higher in the control (48 per cent) than in the C. parvum (23 per cent) group. Toxicity to chemotherapy was not significantly affected by previous C. parvum treatment. Although there were trends for better survival, in the C. parvum patient group, statistically significant activity has not been noted in this study.
    Citation
    Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma. 1986, 73 (2):111-5 Br J Surg
    Journal
    The British Journal of Surgery
    URI
    http://hdl.handle.net/10541/108008
    DOI
    10.1002/bjs.1800730211
    PubMed ID
    3512025
    Type
    Article
    Language
    en
    ISSN
    0007-1323
    ae974a485f413a2113503eed53cd6c53
    10.1002/bjs.1800730211
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Corynebacterium parvum followed by chemotherapy (actinomycin D and DTIC) compared with chemotherapy alone for metastatic malignant melanoma.
    • Authors: Thatcher N, Wagstaff J, Mene A, Smith D, Orton C, Craig P
    • Issue date: 1986 Aug
    • Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    • Authors: Robidoux A, Gutterman JU, Bodey GP Sr, Hersh EM
    • Issue date: 1982 Jun 1
    • Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    • Authors: Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA
    • Issue date: 1991 Jul
    • Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    • Authors: Karakousis CP, Didolkar MS, Lopez R, Baffi R, Moore R, Holyoke ED
    • Issue date: 1979 Nov-Dec
    • DTIC and actinomycin D with and without C. parvum immunotherapy in advanced malignant melanoma.
    • Authors: Halpern J, Catane R, Biran S, Fuks Z
    • Issue date: 1981 May-Jun
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.